ZYMEWORKS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.26 USD | +1.85% |
|
-6.67% | -20.50% |
Presenter SpeechFrank Tang (Analysts)Hello, everyone. I'm Frank Tang with the investment banki...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.26
USD
Average target price
14.17
USD
Spread / Average Target
+71.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.50% | 583M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Transcript : Zymeworks Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 07
